Engineered microorganisms for detection of diseased cells
US-2024118283-A1 · Apr 11, 2024 · US
Anti-cancer agent sensitivity-determining marker
US2017248578A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017248578-A1 |
| Application number | US-201515503878-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 25, 2015 |
| Priority date | Aug 26, 2014 |
| Publication date | Aug 31, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A novel marker for determining sensitivity to an anti-cancer agent is provided. Disclosed is a marker for determining sensitivity to an anti-cancer agent including one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A.
First claim
Opening claim text (preview).
1 . A marker for determining sensitivity to an anti-cancer agent, comprising one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1, and COX5A. 2 . The marker for determining sensitivity to an anti-cancer agent according to claim 1 , wherein the anti-cancer agent is a platinum-based complex anti-cancer agent. 3 . The marker for determining sensitivity to an anti-cancer agent according to claim 1 , wherein the anti-cancer agent is selected from the group consisting of oxaliplatin and a salt thereof. 4 . A method for determining sensitivity to an anti-cancer agent, the method comprising a step of measuring amounts of one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1, and COX5A in a biological sample derived from a cancer patient. 5 . The determination method according to claim 4 , further comprising determining the sensitivity of the cancer patient to an anti-cancer agent by comparing the measurement result with a control level. 6 . The determination method according to claim 4 , wherein the biological sample is a biological sample derived from a cancer patient to which the anti-cancer agent has been administered. 7 . The determination method according to claim 4 , wherein the anti-cancer agent is a platinum-based complex anti-cancer agent. 8 . The determination method according to claim 4 , wherein the anti-cancer agent is selected from the group consisting of oxaliplatin and a salt thereof. 9 . A kit for performing the determination method according to claim 4 , the kit comprising a protocol for measuring the amounts of one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A in a biological sample derived from a cancer patient. 10 . A screening method for an anti-cancer agent sensitivity enhancer, the method comprising employing, as an index, variation in expression of one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A in a cancer cell line or a biological sample derived from a tumor-bearing animal in the presence of an anti-cancer agent. 11 . The screening method according to claim 10 , wherein the anti-cancer agent is a platinum-based complex anti-cancer agent. 12 . The screening method according to claim 10 , wherein the anti-cancer agent is selected from the group consisting of oxaliplatin and a salt thereof. 13 . An anti-cancer agent sensitivity enhancer, which is obtained by the method according to claim 10 . 14 . A composition for cancer treatment, comprising the sensitivity enhancer according to claim 13 in combination with the anti-cancer agent which is a target for sensitivity enhancement. 15 . The composition for cancer treatment according to claim 14 , wherein the anti-cancer agent is a platinum-based complex anti-cancer agent. 16 . The composition for cancer treatment according to claim 14 , wherein the anti-cancer agent is oxaliplatin or a salt thereof.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
specific for metastasis · CPC title
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- G01N33/57535Primary
of the large intestine, e.g. colon, rectum or anus · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017248578A1 cover?
- A novel marker for determining sensitivity to an anti-cancer agent is provided. Disclosed is a marker for determining sensitivity to an anti-cancer agent including one or more molecules selected from the group consisting of PHB, ANXA5, ANXA1, TALDO, C1QBP, IPYR, CRBP1 and COX5A.
- Who is the assignee on this patent?
- Univ Keio, Yakult Honsha Kk
- What technology area does this patent fall under?
- Primary CPC classification G01N33/57535. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Thu Aug 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).